Memantina Stadafarma (Memantine Hydrochloride)

Memantina Stadafarma is a NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive disorders.

• Moderate to severe Alzheimer’s disease: improves cognition, global functioning and daily living activities.
• Alzheimer’s disease combined with cholinesterase inhibitors: provides additional benefit when used together with agents such as donepezil.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor ion channel. By blocking excessive calcium influx caused by prolonged glutamate activation, it reduces excitotoxic neuronal injury while preserving normal synaptic transmission, thereby helping to stabilize cognitive function in Alzheimer’s disease.

Memantina Stadafarma may be associated with several adverse reactions. Patients should be monitored for both common and serious events.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements, manageable with diet.
• Confusion: occasional disorientation.
• Fatigue: feeling of tiredness or reduced energy.
• Hypertension: mild increase in blood pressure.

Serious or Rare Side Effects

• Seizures: rare but may occur, particularly in patients with a seizure history.
• Cardiac arrhythmia: irregular heart rhythms reported in isolated cases.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hallucinations or psychosis: visual or auditory disturbances.
• Liver injury: elevated liver enzymes indicating hepatic stress.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: assess kidney function and adjust dose if necessary.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: observe blood pressure and heart rate regularly.
• Concomitant NMDA antagonists: avoid combined use to reduce neurotoxicity risk.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Stadafarma can interact with several medicines; categorisation helps guide clinical decisions.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can cause severe central nervous system depression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics (e.g., furosemide): may potentiate hypotensive effects.
• Anticholinergic agents: can worsen cognitive side effects.
• Antihypertensives: may enhance blood‑pressure‑lowering action.